May 06, 2005
Sub: Buyback
of the shares of Glaxo SmithKline Pharmaceuticals Ltd.
(500660)
The
members are hereby informed that Glaxo SmithKline Pharmaceuticals Ltd. has
announced buyback (maximum of 2,18,30,636 equity shares) of its fully paid-up
equity shares of face value of Rs.10/- each from the Open Market through
electronic trading mechanism of the Exchange. The Maximum Buyback Price would not exceed Rs.800/-
(Rupees Eight Hundred Only) per equity share
payable in cash for an aggregate amount not exceeding Rs. 23,065.21 lacs.
2. Proposed time table
for buyback:
|
Date of Opening of
the Buyback on BOLT
|
May 09, 2005
|
|
Last date for the
Buyback
|
April 28, 2006 or
when Glaxo SmithKline Pharmaceuticals
Ltd. completes Buy Back to the extent of Rs.23,065.21 lacs under the Buy Back
or such other date as may be determined by Glaxo SmithKline Pharmaceuticals Ltd. at any time even if the
maximum limit of Buy Back of shares has not been reached, whichever is
earlier.
|
3.
Broker
Members for buyback:
The company has appointed
the following BSE member through whom the purchases and settlement on account
of the buyback would be made:
|
Name of the Member
|
Clearing
No
|
|
DSP Merrill
Lynch Ltd.
|
130
|
Members may note that DSP Merrill Lynch Ltd. has the right to buyback shares
of the company in demat as well as physical mode.
4. Details of Buyback
orders on BOLT.
The members may note that the Physical Equity Shares can be offered
for Buyback to the company under scrip code, in rolling settlement, as
mentioned below:
Code No. :
532632
Market
Lot :
1 Share
Scrip ID on BOLT System :
GLAXOSMBBPH
Abbreviated
Name on BOLT System : GLAXOSMITH*
The broker member buying the shares in physical mode under
buyback will accept equity shares certificates of any denomination in buyback
in respect of physical shares, since the market lot of the physical scrip shown
on the BOLT is "one".
The
buyback bid quantity and rate given by the company in respect of the Dematerialized Equity shares of Glaxo SmithKline Pharmaceuticals Ltd. can be viewed through the “Buyback” button as
mentioned in the Exchange Notice No 73405/2001 dated January 4, 2001 under
scrip code no: 500660 (ISIN NO:INE159A01016) in rolling settlement.
5. Buyer
Members can alter the price as well as quantity, as it is applicable in the
normal trading.
6. Circuit
Filters, Margins, Capital Adequacy Norms, Auction, Close out, Bad Delivery,
Arbitration, etc are applicable in case of buyback as in the case of the normal
trading.
7.
Institutional
Investors are allowed to sell in buyback mode.
8. The
documents are available in Corporate Relationship Department for inspection. In
case of any queries /clarifications on the scheme of buyback, members may
please contact the undermentioned persons:
·
Manager
to the Buyback:
DSP Merrill Lynch Ltd.,
10th Floor, Mafatlal Centre,
Nariman Point,
Mumbai – 400 021
Tel: 022 5632 8000
Fax: 022 2204 8518
·
At the
Company :
Ajay A. Nadkarni,
Glaxo SmithKline Pharmaceuticals Ltd.
Dr. Annie Besant Road,
Worli, Mumbai – 400 030
Tel: 022 2495 9595 Extn.
433/145
Email: ajay.a.nadkarni@gsk.com
Ø
At the
Exchange:
Mr. Surindra Rashinkar, Extn: 8306 (For
Clearing & Settlement)
Clearing & Settlement Department.
Help
desk, Extn: 5000 - 5004 (For BOLT
System)
Ms. Smita
Dave, Extn. 8073 (For General Queries)
Corporate
Relationship Department.
Neha Gada
Deputy Manager.
Dept. of Corporate Services